BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 15, 2004
 |  BioCentury  |  Strategy

Fitting in with GlaxoSmithKline

Fitting in with GlaxoSmithKline

Compound Status Target/MOA
Asthma/Chronic obstructive pulmonary disease
Ariflo cilomilast Approvable Phosphodiesterase-4 (PDE-4) inhibitor
Mepolizumab Ph II MAb targeting interleukin-5 (IL-5)
159797 (Theravance deal) Ph II Long-acting adrenergic receptor beta 2 agonists
274150 Ph II

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >